Celldex Therapeutics, Inc.
Develops targeted therapeutics to treat cancer and other conditions
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Celldex's stock with a target price of $66.78, indicating strong growth potential.
Financial Health
Celldex Therapeutics is generating some revenue and cash flow, but its overall financial health is moderate.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CLDX
FDA Cancer Warning: Beyond the Treatment Headlines
The FDA's new boxed warning for a major cancer therapy from Johnson & Johnson and Legend Biotech highlights the serious side effects of advanced treatments. This focus creates an investment opportunity in companies that develop drugs and therapies to help manage these adverse reactions, improving patient quality of life.
Published: October 12, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and regulatory milestones can materially affect value; positive data may drive upside, though trial outcomes are uncertain.
Binary Clinical Risk
Many biotech outcomes are binary — success or failure in trials — which can lead to sharp share price moves and heightened volatility.
Funding & Partnerships
Partnerships or capital raises can accelerate development or dilute shareholders; monitor announcements that affect cash runway and strategic direction.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
